AzurRx BioPharma AZRX shares are trading higher Friday amid a surge in session volume for the day. On Thursday, the company announced it has started dosing in the mid-stage cystic fibrosis study of MS1819.
AzurRx BioPharma Inc is a development-stage biopharmaceutical company. The company is focused on the development of recombinant proteins for the treatment of gastrointestinal diseases and microbiome-related conditions. Its lead product candidate is MS1819, a yeast-derived recombinant lipase for exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis.
AzurRx BioPharma shares were trading up 69.86% at $1.99. The stock has a 52-week high of $2.63 and a 52-week low of 37 cents.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
